Latest Breaking News On - Astrazeneca tagrisso - Page 11 : vimarsana.com

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in Japan for early lung cancer

Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer

United statesUnited kingdomDave fredricksonMasahiro tsuboiDaiichi sankyoThorac oncAstrazeneca tagrissoAdrian kempLe chevalierCompany on twitterInternational agency for research on cancerDepartment of thoracic surgery oncologyNational cancer center hospitalCollaborative groupSingle institution studyArchives pathology lab

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.

United statesAstrazeneca tagrissoMark bergerGenprex incMerck co keytrudaDrug administrationExchange commissionSafety review committeeRecommends advancingIncreased doseSecond cohortFast track designationImmunogene therapyChief medical officerNanoparticle delivery systemPrivate securities litigation reform act

Genprex, Inc secures higher dose approval for REQORSA in combination with Tagrisso Phase 1 clinical trial

Genprex, Inc secures higher dose approval for REQORSA in combination with Tagrisso Phase 1 clinical trial
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Astrazeneca tagrissoMark bergerGenprex incMerck co keytrudaDrug administrationSafety review committeeDelivery systemFast track designation

EGFR Exon 20 Insertion Location Could Be Key Factor in NSCLC Treatment

Data showing that the location of EGFR exon 20 insertion mutations impacts patients' responses to Spectrum's poziotinib could have implications for other EGFR inhibitors.

United statesBoehringer ingelheim gilotrifAstrazeneca iressaGenentech tarcevaAstrazeneca tagrissoZofia piotrowskaJohn heymachAmerican society of clinical oncologyDrug administrationMd anderson cancer centerBoehringer ingelheimCancer centerMassachusetts general hospitalCullinan oncologyDizal pharmaceuticalAmerican society

Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.

United statesRodney varnerRajesh shindeAstrazeneca tagrissoHemant kumarGenprex incMerck co keytrudaPanel participantDrug administrationManufacturing technology operationsDelivery technology landscapeExchange commissionCompany manufacturing leads selectedThought leadersDiscuss advancesLipid nanoparticle delivery systems